Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
142 hedge funds and large institutions have $522M invested in Avidity Biosciences in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 40 reducing their positions, and 19 closing their positions.
4,193% more call options, than puts
Call options by funds: $601K | Put options by funds: $14K
55% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 40
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 143 → 142 (-1)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
6.11% less ownership
Funds ownership: 116.41% → 110.3% (-6.1%)
43% less capital invested
Capital invested by funds: $915M → $522M (-$393M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.99M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.74M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.24M |
| 4 |
JP Morgan Chase
New York
|
+$3.62M |
| 5 |
CC
Casdin Capital
New York
|
+$3.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$17.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.32M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$5.45M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.81M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.71M |
RNAM Hedge Fund Activity: Q3 2023 in Review
142 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2023, worth a combined $522M — down 43% from $915M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RNAM and 18 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 62 added.
The largest buyer was Millennium Management, adding an estimated $5.99M. The largest seller was State Street, cutting an estimated $17.5M.
- 142 institutional investors held Avidity Biosciences (RNAM) as of Q3 2023, down from 143 in Q2 2023.
- Funds reported $522M of Avidity Biosciences stock for Q3 2023, down 43% quarter-over-quarter.
- 18 funds opened new Avidity Biosciences positions in Q3 2023 and 19 closed out, a net change of -1 holder.
- The largest Avidity Biosciences buyer in Q3 2023 was Millennium Management, an estimated $5.99M added.
- The largest Avidity Biosciences seller in Q3 2023 was State Street, an estimated $17.5M sold.
Based on aggregated 13F filings for Q3 2023.